***Background.*** *Enterobacteriaceae* species are important pathogens responsible for a wide variety of serious infections. The tendency of these organisms to develop or acquire resistance to key antimicrobials can lead to MDR strains for which the therapeutic choices are limited. Therefore, tracking and profiling MDR strains is an important aspect of any surveillance initiative. In this study data from The Tigecycline Evaluation Surveillance Trial (TEST) program were analyzed to evaluate the profiles and characteristics of MDR populations from Latin America.

***Methods.*** Between 2008 and 2013 8,907 isolates of *Enterobacteriaceae* from Argentina, Brazil, Chile, Colombia, El Salvador, Guatemala, Honduras, Mexico, Panama, and Venezuela were locally collected, identified, and susceptibility tested (broth microdilution) according to CLSI guidelines. The data were centralized at IHMA for analysis of the MDR populations. MDR was defined as resistance to drugs from three or more different antimicrobial classes.

***Results.*** Of the 8,907 *Enterobacteriaceae* isolates 4,077 (45.8%) had a MDR phenotype; of those MDR 77.7% were from inpatients, 21.8% were blood isolates, 18.2% were from urinary tract specimens, 16.4% were from respiratory tract specimens, 7% were from intra-abdominal infections and 8.7% were from wounds. By species, 33.3 % of MDR were *E. coli*, 28.9% were *K. pneumoniae*, 21% were *E. cloacae*, and 9.1% were *S. marcescens*. The individual antimicrobial profiles for all *Enterobacteriaceae* and the MDR population were as follows:

                   All Enterobacteriaceae (8907)   MDR (4077)                             
  ---------------- ------------------------------- ------------ -------- ------- -------- --------
  Amikacin         89.95                           2            32       79.22   4        64
  Cefepime         77.09                           ≤ 0.5        \> 32    52.86   8        \> 32
  Ceftazidime      0                               ≤ 8          \> 32    0       16       \> 32
  Levofloxacin     64.12                           0.25         \> 8     33.87   8        \> 8
  Meropenem        95                              ≤ 0.06       0.5      89.38   ≤ 0.06   2
  Pip-tazo         74.59                           4            \> 128   48.71   32       \> 128
  Tigecycline^a^   96.68                           0.5          2        93.3    0.5      2

^a^FDA breakpoints used for tigecycline

***Conclusion.*** The MDR rate among *Enterobacteriaceae* is very high in Latin America, especially among inpatient isolates. The MDR phenotype was also prevalent among isolates from the key infection sites. Meropenem and tigecycline were the most active drugs against the MDR population. The critical importance of this phenotype warrants careful and ongoing surveillance.
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